SomnoMed Limited (ASX:SOM)

Market Cap	139.26M +43.2%
Revenue (ttm)	111.49M +21.6%
Net Income	-3.46M
EPS	-0.02
Shares Out	218.44M
PE Ratio	n/a
Forward PE	47.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,550
Average Volume	289,356
Open	0.6500
Previous Close	0.6550
Day's Range	0.6370 - 0.6550
52-Week Range	0.3700 - 0.9450
Beta	0.92
RSI	35.81
Earnings Date	Feb 20, 2026

About SomnoMed

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient’s mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient’s upper te...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1987
• Employees: 300
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: SOM

Financial Performance

In fiscal year 2025, SomnoMed's revenue was 111.49 million, an increase of 21.65% compared to the previous year's 91.65 million. Losses were -3.46 million, -71.77% less than in 2024.